Does RELUGOLIX Cause Hormone-refractory prostate cancer? 5 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Hormone-refractory prostate cancer have been filed in association with RELUGOLIX (Orgovyx). This represents 0.0% of all adverse event reports for RELUGOLIX.
5
Reports of Hormone-refractory prostate cancer with RELUGOLIX
0.0%
of all RELUGOLIX reports
0
Deaths
0
Hospitalizations
How Dangerous Is Hormone-refractory prostate cancer From RELUGOLIX?
Of the 5 reports.
Is Hormone-refractory prostate cancer Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RELUGOLIX. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does RELUGOLIX Cause?
Hot flush (6,845)
Fatigue (5,203)
Therapy interrupted (3,251)
Incorrect dose administered (1,917)
Asthenia (1,718)
Arthralgia (1,385)
Diarrhoea (1,383)
Product dose omission issue (1,189)
Dizziness (1,146)
Constipation (902)
What Other Drugs Cause Hormone-refractory prostate cancer?
RADIUM RA-223 DICHLORIDE (441)
LEUPROLIDE (180)
DOCETAXEL (123)
ENZALUTAMIDE (120)
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (110)
DAROLUTAMIDE (104)
ABIRATERONE (83)
PREDNISONE (58)
CABAZITAXEL (57)
BICALUTAMIDE (50)
Which RELUGOLIX Alternatives Have Lower Hormone-refractory prostate cancer Risk?
RELUGOLIX vs REMDESIVIR
RELUGOLIX vs REMERON
RELUGOLIX vs REMICADE
RELUGOLIX vs REMIFENTANIL
RELUGOLIX vs REMIMAZOLAM